Forman Stephen J. 4
4 · LIXTE BIOTECHNOLOGY HOLDINGS, INC. · Filed Dec 3, 2020
Insider Transaction Report
Form 4
Forman Stephen J.
Director
Transactions
- Purchase
Common Stock
2020-11-30$4.75/sh+21,053$100,002→ 37,720 total(indirect: By Trust) - Purchase
Warrants to Purchase Common Stock
2020-11-30$4.75/sh+21,053$100,002→ 21,053 total(indirect: By Trust)Exercise: $5.70From: 2020-11-30Exp: 2025-11-30→ Common (21,053 underlying)
Holdings
- 16,667
Options to Purchase Common Stock
Exercise: $0.96From: 2016-05-13Exp: 2021-09-13→ Common Stock (16,667 underlying) - 8,333
Options to Purchase Common Stock
Exercise: $6.60From: 2019-05-22Exp: 2024-05-22→ Common Stock (8,333 underlying) Common Stock
- 8,333
Options to Purchase Common Stock
Exercise: $0.90From: 2017-10-16Exp: 2022-10-16→ Common Stock (8,333 underlying) - 16,667
Options to Purchase Common Stock
Exercise: $0.96From: 2017-05-13Exp: 2022-09-13→ Common Stock (16,667 underlying) - 16,667(indirect: By Trust)
Warrants to Purchase Common Stock
Exercise: $6.00From: 2018-12-07Exp: 2022-12-07→ Common Stock (16,667 underlying)
Footnotes (1)
- [F1]The reporting person acquired 21,053 Units, each Unit consisting of one share of Common Stock and a five year warrant at an exercise price of $5.70 per share. The purchase price for a Unit was $4.75 per Unit.